Sun Pharma’s head of biologics marketing Maureen Shannon said, “We are so honored to partner with Art Garfunkel to share his ILUMYA story and to bring greater awareness to the impact psoriasis has ...

A decade-long study found that obesity was associated with a significantly increased risk for biologic treatment failure in ...

Discover a study that assessed the risk of hospitalisation for serious infections based on different categories of systemic ...

Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...

Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be comple ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients ...

Art Garfunkel, 83, opened up for the first time about his long standing battle with psoriasis, which recently forced him to ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...